PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB:PBIO)
(“PBI” and “the Company”) was recently interviewed on Uptick Newswire’s “Stock Day” podcast. Schumacher discussed the Company’s
continued financial success, the significant amount of debt the Company has converted into equity over the past 30 days, and the
Company’s plans to up-list to a national exchange before the year is out.
“Although we are a QB company on the OTC Marketplace, we run the Company as if we were NASDAQ or NYSE-Amex listed. This is
important, since we have expectations of moving up to a national stock exchange before the end of this year,” commented
Schumacher.
Schumacher stresses that the Company has been working diligently to meet the requirements necessary to up-list PBIO to a
national exchange. One such requirement is that the Company must show strong, positive stockholders equity. The Company made
tremendous strides in this regard when they announced the conversion of over $13.6 million of debt into equity over the past 30
days.
Pressure BioSciences is unique in the biological field. “We’re changing a paradigm that’s existed in labs for maybe 50 years,”
said Schumacher. The Company’s pressure cycling technology (“PCT”) carefully breaks cells open while minimizing damage to the
important internal contents such as DNA, RNA, lipids, and proteins. Many of the other extraction methods used routinely by as many
as 500,000 researchers worldwide involve breaking cells open in a more volatile and destructive ways that can actually damage the
biomolecule contents or put researchers at risk. PBI’s unique PCT method is more like squeezing a sponge, and the number of
squeezes and level of pressure necessary for each unique cell type can be programmed into a computer that is part of their
instrument. Individualizing profiles for human, plant, animal, and other normal or cancer cell types can promote consistency in
research while significantly reducing variability, so very important in scientific research.
“High pressure has not really been utilized that much in the lab up to now, mainly because until we came along, there was really
no way of safely getting high pressure into the lab. We use pressures up to 6 times the pressure you would feel if you were
standing at the bottom of Mariana’s Trench, with six miles of ocean on top of you. Now that is pressure!” Schumacher went on to
mention that their pressure chambers can safely reach levels up to 100,000 PSI, a staggering high in the industry.
With a market cap of about $4.2 million and shares selling at just under $3, Jolly and believes that now is a great time for
investors to get involved with PBI. “It’s an extremely undervalued company. It’s one of those undiscovered gems for which investors
are always looking. The Company has done very well over the past 18-24 months, and we expect they will continue to do well, yet
their stock price is actually down about 75% over that time. At some point, we believe they will be discovered,” said Jolly. “Until
then, in our opinion, the stock price is not even close to a true reflection of the value of this company.”
To hear more about the Company’s recent debt to equity conversions, its partnership with ISS Inc., and its globally-used
flagship products, please click the following link to hear the full interview on Uptick Newswire’s website.
https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-6/
Investors Hangout is a proud sponsor of Uptick Newswire’s “Stock Day” Podcast, and encourages listeners to visit the
company’s board on their website.
http://www.investorshangout.com
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based
solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static)
and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform
that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based
products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control,
soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in
the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from
BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable
nano-emulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended
shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal
technologies.
Contact
Pressure BioSciences, Inc.
Richard T. Schumacher – President & CEO
508-230-1828
Safe Harbor Statement
Statements contained in this press release regarding PBIO's intentions,
hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and
assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are
not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes
no obligation to update any of the information included in this release, except as otherwise required by law.
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and
bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network
“Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire.
For more information about PBIO and this press release, please click on the following website link:
http://www.pressurebiosciences.com
